Joshua Burns

Congratulations to GRIN Advisory Board member, Professor Joshua Burns

by | Oct 19, 2023 | 0 comments

Congratulations to GRIN Advisory Board member, Professor Joshua Burns, for being recognized by the Australian Academy of Health and Medical Sciences for his outstanding contributions to medical and health sciences.

“Fellows are elected by their peers for their significant contributions to health and medical sciences – it is a selective process that recognizes the best and brightest in Australia and highlights those who are truly making a difference in health,” said the Academy’s Interim President Professor Ingrid Scheffer AO FRS FAA FAHMS.

Professor Burns is the inventor of, a web-based scoring system for monitoring response to therapy, housing key clinical trial endpoints such as the Charcot-Marie-Tooth Pediatric Scale (CMTPedS), CMT Functional Outcome Measure (CMT-FOM), CMT Infant Scale (CMTInfS), Rasch-modified CMT Neuropathy Score (CMTNSv2-R) and items from the 1000 Norms Project. This work is critical to the preparation for clinical trials for the treatment of the CMT.

HNF recently launched its CMT Pediatric Natural History Study project in which clinical evaluation data will be collected in the Global Registry for Inherited Neuropathies (GRIN), in addition to the patient-reported data and genetic reports. In August, an associate of Dr. Burns, Dr. Kayla Cornett, PhD, trained and certified the Physical Therapy and Occupational Therapy staff at both Lurie’s Children’s Hospital and Arkansas Children’s Hospital. The certification is required to conduct the CMT Pediatric Scale and the CMT Infant Scale, both of which are a part of the clinical evaluation for our CMT Pediatric Natural History project. This study is currently in progress.

If you would like to inquire about participation in this study, please contact [email protected].

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news